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A Phase 2 randomized, double-blind, multicenter study to evaluate efficacy and safety of 5 
intravenous iclaprim versus vancomycin for the treatment of nosocomial pneumonia suspected or 6 
confirmed to be due to Gram-positive pathogens  7 
 8 
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*The data in this manuscript were presented at ID Week 2015 in San Diego, California on 12 
October 9-11, 2015. 13 
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     Abstract 22 
 23 
Purpose: The primary objective of this Phase 2 study was to compare the clinical cure rates of 24 
two iclaprim dosages with vancomycin in the treatment of patients with nosocomial pneumonia 25 
suspected or confirmed to be caused by Gram- positive pathogens.  26 
Methods: This was a double-blind, randomized, multicenter study. A total of 70 patients was 27 
randomized 1:1:1 to iclaprim 0.8 mg/kg IV q12h (iclaprim q12h; n = 23), iclaprim 1.2 mg/kg IV 28 
q8h (iclaprim q8h; n =24), or vancomycin 1 g IV q12h (vancomycin; n =23) for 7-14 days. The 29 
primary endpoint was clinical cure in the intent-to-treat (ITT) population at test of cure (TOC; 7 30 
± 1 days post treatment) visit.   31 
Findings: Cure rates in the ITT population were 73.9% (17 of 23), 62.5% (15 of 24), and 52.2% 32 
(12 of 23) at the TOC visit in the iclaprim q12h, iclaprim q8h, and vancomycin groups, 33 
respectively (iclaprim q12h versus vancomycin p = 0.13; and iclaprim q8h versus vancomycin p 34 
= 0.47). The death rates within 28 days of the start of treatment were 8.7% (2 of 23), 12.5% (3 of 35 
24), and 21.7% (5 of 23) for the iclaprim q12h, iclaprim q8h, and vancomycin groups, 36 
respectively (no statistically significant differences). The adverse event profile of both iclaprim 37 
dosaging regimens were similar to that of vancomycin.  38 
Implications: Iclaprim showed both comparable clinical cure rates and safety profile with 39 
vancomycin among patients with nosocomial pneumonia. Iclaprim could be an important new 40 
therapeutic option for treatment of nosocomial pneumonia, and a pivotal clinical trial is 41 
warranted to evaluate its safety and efficacy in this indication.  42 
Study Registration Number: NCT00543608 43 
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Introduction 46 
Nosocomial pneumonia, which includes hospital acquired pneumonia (HAP) and 47 
ventilator associated pneumonia (VAP), is a serious and life threatening infection. Nosocomial 48 
pneumonia is the most common hospital acquired infection (HAI) accounting for 22% of all 49 
HAIs.1 Based on data reported to the National Healthcare Safety Network at the Centers for 50 
Disease Control and Prevention, 2011-2014, Staphylococcus aureus accounts for 25% of VAP, 51 
the most common cause of VAP.2  Despite existing antibiotic therapies, the all-cause mortality 52 
rate associated with nosocomial pneumonia is 20-50%; and a meta-analysis of randomized VAP 53 
prevention studies estimated the attributable mortality could reach beyond 13%.3  VAP, 54 
furthermore, prolongs mechanical ventilation by 8 to 12 days, hospitalization by 12 to 13 days 55 
and is associated with an excess cost of approximately $40,000 per patient.4,5  New therapeutic 56 
options, with improved efficacy, pharmacodynamics, and/or safety are thus needed for 57 
nosocomial pneumonia especially with the increasing prevalence of multidrug Gram-negative 58 
and Gram-positive resistant bacteria and the associated poor outcomes and high costs.6   59 
Iclaprim represents a new generation diaminopyrimidine, which inhibits bacterial 60 
dihydrofolate reductase, and is active against emerging drug-resistant pathogens.7,8  Iclaprim 61 
exhibits potent in vitro activity against Gram-positive pathogens associated with acute bacterial 62 
skin and skin structure infections and nosocomial pneumonia including methicillin-resistant S. 63 
aureus, vancomycin-intermediate S. aureus, vancomycin-resistant Enterococcus spp., and 64 
Streptococcus spp. 7  Iclaprim demonstrates rapid in vitro bactericidal activity in time kill studies 65 
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in human plasma.9  Iclaprim concentrates in epithelial lining fluid and alveolar macrophages at 66 
concentrations of 20 to 40 fold that of its plasma levels resulting in pulmonary concentrations 67 
exceeding the MIC90 for Gram-positive respiratory pathogens.10  Because of these characteristics 68 
of iclaprim, iclaprim is potentially well suited for treating patients with nosocomial pneumonia 69 
caused by or suspected Gram-positive bacteria.  We present a Phase 2 study comparing the 70 
outcomes of patients treated with iclaprim to vancomycin for nosocomial pneumonia suspected 71 
or confirmed to be due to Gram-positive pathogens. 72 
 73 
 74 
Methods 75 
Study Design 76 
  This Phase 2 study was a multi-center, double-blind, randomized 1:1:1, parallel group 77 
study with three treatment arms: iclaprim 0.8 mg/kg IV q12h (iclaprim q12h); iclaprim 1.2 78 
mg/kg IV q8h (iclaprim q8h); or vancomycin 1g IV q12h (vancomycin) (NCT00543608).  79 
Patients were enrolled between November 17, 2007 and January 14, 2009.  The institutional 80 
review board at each site approved the protocol, and all patients or their authorized 81 
representative provided written informed consent. ͒Patients who met eligibility requirements, 82 
which are listed in the patients section below, were randomly assigned, using the method of 83 
block randomization with stratification, with equal allocation to one of the three treatment arms 84 
using the mechanism of an interactive voice response system as a part of a central randomization 85 
process with prospective stratification for APACHE II score11 (8 to 19 versus 20 to < 25) and 86 
pneumonia type (HAP or VAP) given potential different outcomes associated with these 87 
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variables.  ClinPhone, the randomization center who generated the random allocation sequence, 88 
ZDVSURYLGHGZLWKWKHSDWLHQW¶VGHPRJUDSKLFLQIRUPDWLRQZHLJKWSQHXPRQLDW\SHDQG89 
APACHE II score.  Each patient, who was enrolled by Parexel International, was assigned a 90 
unique patient number by the central randomization system upon meeting all eligibility 91 
requirements.  Numbered randomization envelopes, containing treatment assignment and 92 
treatment preparation and infusion directions, were provided to WKHVLWHV¶SKDUPDFLVWVGHVLJQHHV 93 
 94 
Primary and Secondary Objectives  95 
The primary objective of the study was to compare the clinical cure rates at test of cure 96 
(TOC; 7 ± 1 days post treatment) in the ITT population treated with iclaprim q12h or iclaprim 97 
q8h regimens with vancomycin among patients with nosocomial pneumonia suspected or 98 
confirmed to be due to Gram-positive pathogens. The secondary objectives of the study were: (1) 99 
mortality within 28 days after the start of treatment; (2) microbiological outcomes at end of 100 
therapy (EOT) and TOC; and (3) safety and tolerability of the two dosages of iclaprim compared 101 
with vancomycin.   102 
 103 
Definitions 104 
+$3ZDVGHILQHGDVDSQHXPRQLDRFFXUULQJKRXUVDIWHUDGPLVVLRQZKLFKZDVQRW105 
incubating at the time of admission.12  9$3ZDVGHILQHGDVDSQHXPRQLDRFFXUULQJKRXUV106 
after endotracheal intubation.12 The investigators, caregivers, and patients remained blinded to 107 
the study drug treatment allocation. Only the pharmacist/designee at each site who prepared the 108 
sWXG\SURGXFWIRULQIXVLRQZDVDZDUHRISDWLHQWV¶WUHDWPHQWDVVLJQPHQWV͒Patients submitted 109 
respiratory samples and two blood culture specimens at baseline for Gram stain and culture.  110 
 6 
Patients received their first dose of randomly allocated study medication within 24 hours after 111 
randomization. Study medications were administered for at least 7 days with continuation of 112 
treatment up to 7 additional days at the discretion of the investigator.  This administration is in 113 
accordance with the American Thoracic Society and Infectious Disease Society of America 114 
(ATS/IDSA) guidelines at the time the study was conducted.12 Patients were evaluated at a 115 
baseline assessment and daily during their treatment course, EOT, TOC, and at a late follow-up 116 
visit (LFU - 7±14 days after the TOC visit) (Figure 1).   117 
  Clinical cure was defined as complete resolution of all signs and symptoms of pneumonia, 118 
for both HAP and VAP, (tachypnea, cough, rigors or shaking chills, rales, pulmonary 119 
consolidation, hypoxia, pleuritic chest pain, purulent sputum production and respiratory 120 
secretions), improvement or lack of progression of all abnormalities on chest radiograph, and no 121 
further antibiotic treatment at the TOC visit.  Safety was assessed by Common Terminology 122 
Criteria for reported treatment emergent adverse events (TEAEs), serious adverse events (SAEs), 123 
hematology, clinical chemistry, urinalysis, vital signs, physical examinations, and 124 
electrocardiograms (ECGs). 125 
 126 
Patients  127 
The study was intended to randomize 135 patients who fulfilled criteria for the ITT 128 
population from 51 study sites in 7 countries. Formal statistical sample size considerations were 129 
not applied to this study.  A sample size of approximately 25 patients per group that fulfilled 130 
medical criteria for the modified intent-to-treat (MITT) population was determined to be a 131 
clincially reasonable number of patients for this study.  It was anticipated that approximately 60% 132 
of enrolled patients would be evaluable for efficacy assessments.  Based on this calculation, a 133 
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planned sample size of 135 patients included in the ITT population was expected to result in 134 
approximately 25 evaluable patients per treatment arm and provide a reasonable number of 135 
patients to assess the safety of iclaprim.  However, recruitment was stopped prematurely due to 136 
financial reasons only.  Figure 2 shows the disposition of patients.  The resulting ITT and safety 137 
populations contained 70 patients (iclaprim q8h (n = 24), iclaprim q12h (n =23), and vancomycin 138 
(n = 23)).  The ITT population was defined as all randomized patients who received at least one 139 
dose of study medication.  All patients with a culture-confirmed Gram-positive pathogen at 140 
baseline were included in a MITT population. The clinically evaluable (CE) population included 141 
all patients in the ITT population who received at least 5 full days of study medication, or at least 142 
2 full days of study treatment for patients whose clinical outcome was considered a failure, and 143 
had no major protocol violations. 144 
0DOHDQGIHPDOHSDWLHQWV\HDUVRIDJHZHUHLQFOXGHGLQWKHVWXG\LIWKH\or an 145 
authorized representative (for VAP patients) had given informed consent, had suspected or 146 
confirmed acute HAP or VAP due to Gram-positive pathogens, and had venous access available 147 
for intravenous dosing.  Suspected or confirmed acute HAP or VAP required all randomized 148 
patients to have at least two of the following signs and symptoms: cough, new onset of purulent 149 
sputum production or a change (worsening) in character of the sputum, auscultatory findings on 150 
pulmonary examination of rales and/or pulmonary consolidation, dyspnea, tachypnea or 151 
hypoxemia with a partial pressure oxygen (PO2) <60 mmHg and at least two of the signs and 152 
symptoms fever (oral temperature >38ºC/100.4ºF) or hypothermia (<35ºC/95.2ºF), respiratory 153 
UDWH!EUHDWKVPLQSXOVHUDWHEHDWVPLQDOWHUHGPHQWDOVWDWXVOHXNRF\WRVLVZLWKZKLWH154 
blood cell (WBC) count >10,000/mm6or leukopenia with WBC count <4,500/mm6; and/or >15% 155 
immature neutrophils (bands).  In addition, all patients had a new pulmonary infiltration 156 
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documented by chest X-ray, a suitable respiratory specimen for culture, and Gram stain, with 157 
indication of Gram-positive pathogen, and clinical pulmonary infection scores (CPIS) > 6.  The 158 
clinical pulmonary score consists of a composite score of temperature, blood leukocytes, tracheal 159 
secretions, oxygenation, pulmonary radiography, progression of pulmonary infiltrate, and culture 160 
of tracheal aspirate.  A CPIS score > 6 at baseline is considered suggestive of pneumonia.13 161 
Patients were excluded if they had an Acute Physiology and Chronic Health Evaluation 162 
(APACHE) II9 VFRUHRU (Patients with APACHE II scores of  were excluded because 163 
outcomes may not be reflective of study drug); pneumonia due to Gram-positive organisms 164 
resistant to either study medication; had an underlying medical condition that precluded 165 
treatment with iclaprim or vancomycin (i.e., previous allergic reactions to trimethoprim, 166 
trimethoprim-sulfamethoxazole, or vancomycin); received previous systemic antimicrobial 167 
therapy, effective against Gram-SRVLWLYHSDWKRJHQVIRUKRXUVZLWKLQKRXUVEHIRUH168 
enrollment; if they required empiric treatment for suspected or confirmed concurrent Gram-169 
negative bacterial infection with antibiotics other than aztreonam; documented or suspected 170 
meningitis, endocarditis, or osteomyelitis; known or suspected hypersensitivity to trimethoprim, 171 
iclaprim or vancomycin; severe hepatic disease or bilirubin >1.5X upper limit of normal and/or 172 
alanine transaminase >3X ULN, baseline QTc interval >470 msec; severe renal impairment 173 
defined as creatinine clearance <30 mL/minute;  absolute neutrophil count <500 cells/mm6; or 174 
pulmonary disease that precluded evaluation of therapeutic response (e.g. lung cancer, active 175 
tuberculosis, cystic fibrosis, or granulomatous disease). 176 
 177 
Study Treatments 178 
Iclaprim was administered at 0.8 mg/kg IV q12h or 1.2 mg/kg IV q8h.  These two dosages were 179 
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chosen because of previous efficacy and safety evaluation in Phase 2/3 clinical studies.14, 15 The 180 
0.8 mg/kg IV q12h dose was expected to be as effective as vancomycin based on data from a 181 
Phase 2 study in patients with cSSSI.  Given the different indication of pneumonia and the longer 182 
infusion rate (60 minutes), the study included a higher dosing regimen (1.2 mg/kg IV q8h) which 183 
was also expected to be safe.  Based on the tolerability demonstrated in several clinical studies 184 
for doses up to 1.6 mg/kg q12h (infused over 30 minutes), it appeared clinically justified to 185 
increase the total iclaprim daily dose, thereby enabling an investigation of a possible dosing 186 
effect of iclaprim in the treatment of pneumonia.  At the time of the study, country specific 187 
prescribing recommendations consistently indicated vancomycin should be administered at 1 g 188 
IV q12h, however, investigators could prescribe a different dose according to institutional 189 
guidelines or based on a specifLFSDWLHQW¶VFRQGLWLRQ.  In addition, local prescribing 190 
recommendations were followed for dose adjustments of vancomycin in patients with renal 191 
impairment.  The maintenance dose of vancomycin was selected according to local standard of 192 
FDUHWDNLQJLQWRFRQVLGHUDWLRQWKHSDWLHQW¶VERG\ZHLJKWFUHDWLQLQHFOHDUDQFHDQGSODVPDOHYHOV193 
of vancomycin, based on institutional guidelines.  If the institution used a standard vancomycin 194 
dosage that did not match the recommended dosing, the unblinded pharmacist used the former to 195 
prepare infusions for patients who were assigned to the vancomycin arm, notably keeping the 196 
same infusion volume.  For each patient the investigator provided the creatinine clearance or data 197 
for calculation to the site pharmacist; based on the creatinine clearance level, the site pharmacists 198 
adjusted the vancomycin dosage for further infusions on an as needed basis according to either 199 
the package insert or local requirements.  Both iclaprim and vancomycin were infused over 60 200 
minutes in 2 bags 120mL each.  To maintain the study blinding and to accommodate the 201 
different dosages, all patients received four infusions per day at nominal hours 0, 8, 12, and 16.  202 
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The protocol permitted concomitant antibiotic treatment with aztreonam for patients 203 
whose pneumonia was caused by mixed (Gram-positive and Gram-negative) pathogens.  204 
 205 
Duration of Treatment  206 
Study treatment was initiated within 24 hours after patient randomization. Planned treatment 207 
duration was 7 to 14 days. Study medication was administered beyond 7 days only for patients 208 
with persistent signs and symptoms consistent with active infection in accordance with 209 
guidelines.12  210 
 211 
Statistical Methods  212 
The statistical analyses evaluated the two dosages of iclaprim compared with vancomycin. An 213 
overall quantitative evaluation of efficacy and safety was performed comparing the 3 treatment 214 
groups. Demographics and baseline characteristics were summarized using descriptive statistics. 215 
The primary efficacy analysis was performed in the ITT, MITT and the CE populations. The 216 
)LVKHU¶V([DFW7HVWZDVXVHGWRFRPSDUHWKHFOLQLFDOFXUHUDWHVIRU the two iclaprim dosages 217 
versus vancomycin using a 2-sided test at the 2.5% level of significance, corresponding to a 2-218 
sided 95% confidence intervals (CI), based on the normal approximation to the binomial 219 
distribution. The 2-sided CIs were calculated for the difference in proportions of clinical cure 220 
between iclaprim groups, and for the proportion of patients with clinical cure in each treatment 221 
group.  A similar analysis was conducted for the proportion of patients who had died by Day 28.   222 
A Cox Proportional Hazard analysis was conducted to determine treatment effect on the time of 223 
death in the ITT population within 28 days from start of treatment.  By-patient and by-pathogen 224 
bacteriological outcomes at EOT and TOC were presented as frequency distributions of 225 
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outcomes by treatment group for patients with a confirmed Gram- positive pathogen at baseline.  226 
The incidence of TEAEs was summarized at the overall patient level, Medical Dictionary for 227 
Regulatory Activities (MedDRA) system organ class level, and preferred term level. Separate 228 
tabulations were provided by severity and relationship to study medication and for SAEs. 229 
Laboratory data, vital signs and ECGs were evaluated by presentation of summary statistics of 230 
raw data and changes from baseline.  231 
 232 
 233 
Results 234 
Demographics  235 
The trial enrolled 70 patients (iclaprim q12h (n = 23), iclaprim q8h (n= 24), and vancomycin (n = 236 
23)).  Tables 1 and 2 show that the baseline and demographic characteristics of patients treated 237 
with either iclaprim or vancomycin were comparable. Treatment groups were similar for baseline 238 
CPIS, laboratory parameters, vital signs, physical examinations, X-rays, and ECG evaluations. In 239 
addition, no notable differences among treatment groups with respect to prior medications and 240 
treatments or study drug compliance were observed. All patients with suspected or confirmed 241 
mixed (Gram-positive and aztreonam susceptible Gram-negative) pathogens were treated with 242 
aztreonam.  If the patient had a confirmed Gram-negative pathogen resistant to aztreonam, the 243 
protocol allowed for piperacillin-tazobactam. All patients randomized had APACHE II scores of 244 
8-19, except for two patients who were in the 20-25 range (one patient in the iclaprim q12h and 245 
one patient in the iclaprim q8h treatment group).  The mean and median number of treatment 246 
days was 7 (standard deviation [SD] 2.6) in the iclaprim q8h group, 9 (3.4) in the iclaprim q12h 247 
group, and 7 (3.5) in the vancomycin group. 248 
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 249 
Efficacy Results  250 
Primary Endpoint 251 
In the ITT population, a clinical cure was reported at TOC for 17 patients (73.9%) in the iclaprim 252 
q12h group, 15 patients (62.5%) in the iclaprim q8h group, and 12 patients (52.2%) in the 253 
vancomycin group (Table 3; iclaprim q12h versus vancomycin p = 0.13, and iclaprim q8h versus 254 
vancomycin p = 0.47).  These differences were not statistically significant (neither between the 255 
two dosages of iclaprim nor between either dosages of iclaprim and vancomycin). These 256 
response rates with iclaprim and vancomycin were similar at TOC in the MITT and CE 257 
populations (Table 3).  258 
 259 
Secondary Endpoints 260 
In the ITT population, the clinical cure rates at EOT were 83% (19 of 23), 75% (18 of 24), 261 
and 57% (13 of 23) for iclaprim q12h, iclaprim q8h, and vancomycin, respectively (iclaprim 262 
q12h versus vancomycin p = 0.06, and iclaprim q8h versus vancomycin p = 0.18).  In the ITT 263 
population, the death rates within 28 days from the start of treatment were 12.5% (3 of 24) and 264 
8.7% (2 of 23) for the iclaprim q8h and iclaprim q12h regimens, respectively, and were 21.7% (5 265 
of 23) for the vancomycin group (not statistically significant) (Table 3).  No significant treatment 266 
effect on the time to death in the ITT population was found within 28 days from the start of 267 
treatment with the Cox Proportional Hazard analysis (vancomycin vs. iclaprim q12h comparison, 268 
p = 0.25, hazard ratio = 2.6, and 95% CI = 0.5, 1.6 or iclaprim q8h comparison, p =0.42, hazard 269 
ratio = 1.3, CI = 0.7, 2.7).  270 
For the microbiological outcome at EOT and TOC, although all 70 patients presented 271 
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with a Gram-positive stain (ITT population), a culture-confirmed Gram-positive pathogen could 272 
be identified at baseline (MITT population) for only 21 patients (30%). The most common 273 
isolated pathogen was S. aureus (15 MITT patients, 71%) and 6 of these (40%) were MRSA.  274 
The other Gram-positive organisms isolated are shown in Table 2.  Among the mixed infections, 275 
all, but one, Gram-negative bacteria were susceptible to aztreonam.  One patient randomized to 276 
vancomycin treatment had an Acinetobacter baumannii, which was resistant to aztreonam but 277 
susceptible to and treated with piperacillin-tazobactam (MIC 8/2 mcg/mL). The iclaprim and 278 
vancomycin MIC range for the 15 S. aureus isolates was 0.03-2 mcg/mL and 0.5-1 mcg/mL, 279 
respectively.  Due to the low numbers in the treatment groups and the associated imbalances, 280 
statistical evaluation of bacteriological outcomes or overall therapeutic responses at EOT and 281 
TOC (by-patient or by-pathogen) were not considered meaningful.  Among patients infected 282 
with S. aureus, clinical cure was 5 of 7 in the iclaprim q12h group, 3 of 5 in the iclaprim q8h 283 
group and 0 of 3 in the vancomycin group.  No vancomycin trough concentrations were collected 284 
during the study.  There was only one clinical failure among the 15 patients (6.7%) in the MITT 285 
population treated with iclaprim.  This patient was infected with MRSA, and there was no 286 
association with a high MIC. Two of six patients (33%) in the MITT population treated with 287 
vancomycin were clinical failures.  288 
 289 
Safety Results  290 
The two dosages of iclaprim and vancomycin were generally well tolerated (Table 4). No 291 
new or unexpected safety concerns emerged.  The high incidence of TEAEs and the number of 292 
deaths reported during the study were not surprising considering the clinical indication under 293 
study, concomitant illnesses, and medical history of these patients. Overall drug-related TEAEs 294 
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occurred in 12.5%, 17.4%, and 30.4% of patients in the iclaprim q8h, iclaprim q12h and 295 
vancomycin treatment groups, respectively.  Only one specific type of TEAE, cardiac failure in 296 
three patients treated with iclaprim q8h, was reported for more than 10% of patients in any 297 
treatment group; cardiac failure was not considered related to study drug in any of the three 298 
patients.  SAEs were reported for 19 patients: 16.7%, 21.7% and 43.5% for iclaprim q8h, 299 
iclaprim q12h and vancomycin, respectively. There were 10 deaths within 28 days after initiation 300 
of treatment: two, three and five deaths occurred in iclaprim q12h, iclaprim q8h, and vancomycin 301 
groups, respectively; none was considered related to study treatment.  Table 5 lists the causes 302 
and timing of deaths relative to study drug administration.  303 
Most of the abnormalities and changes in laboratory values were not clinically significant. 304 
One patient treated with vancomycin had a notable increase in creatinine and blood urea nitrogen 305 
and was withdrawn from the study but included in the ITT study outcome. There were no 306 
significant differences in mean values or mean changes in urinalysis results, vital signs or 307 
physical examinations during treatment, or at EOT, TOC and follow-up between treatment 308 
groups. Four patients had shifts in ALT/AST values to >3X upper limits of normal (ULN) during 309 
treatment: two patients in the iclaprim q8h group and two in the vancomycin group. There were 310 
no ALT/AST increases to͒>5X ULN. No patients had bilirubin increases >2X ULN.  311 
Abnormal ECGs were observed in all 3 groups at baseline and during treatment. Most of 312 
the ECG changes were not clinically significant.  During treatment, 22 patients had QTcB and/or 313 
QTcF intervals >500 msec or increased by͒>30 msec compared with baseline: 11, 7 and 4 314 
patients in the iclaprim q12h group, iclaprim q8h group, and vancomycin groups, respectively. 315 
The QTc prolongation was reported as an AE in 2 patients in the iclaprim q12h group and one of 316 
these patients was withdrawn from treatment. One patient in the iclaprim q12h group, who had a 317 
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medical history that included hypetrophic cardiomyopathy, paroxysmal atrial fibrillation, arterial 318 
hypertension, coronary artery disease, first degree atrioventricular block, experienced ventricular 319 
tachycardia after one day of treatment, and died the same day. No increase in the QTc interval 320 
was registered for this patient.  The patient had a post infusion QTc interval of 410 msec, which 321 
was repeated a minute later with a reading of 389 msec.  The patient had a 3-year history of 322 
cardiac arrhythmias and the event was judged unrelated to study drug treatment. One patient in 323 
the vancomycin group was withdrawn for sick sinus syndrome which the investigator judged as 324 
probably treatment related. ECG showed flattened T-waves, QTc interval of 454 msec and a 325 
heart rate 124-126 bpm without any other abnormalities 326 
 327 
Discussion  328 
This abridged Phase 2 study showed that both iclaprim q12h and iclaprim q8h dosages 329 
were at least as effective as vancomycin in the treatment of nosocomial pneumonia caused by 330 
Gram-positive organisms with respect to clinical cure rates at EOT and TOC and Day 28 331 
mortality rates. Both iclaprim dosages and vancomycin were generally well tolerated. No new or 332 
unexpected suspected adverse events emerged. Although transient and reverisble QTc 333 
prolongation was identified more frequently among patients receiving iclaprim, no notable 334 
differences in the incidence of TEAEs among the treatment groups were observed.  335 
There are limitations to this Phase 2 study.  Most notably, the study was stopped for 336 
financial reasons after randomization of 70 patients of a planned 135 patients. The statistical 337 
power of the study was therefore compromised with an increase in the risk of a Type II error.  338 
Second, the vancomycin dosage used in this study was 1 g IV q12h, which is a lower dosage 339 
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compared to the currently recommended weight based dosaging of 15 mg/kg every 12h with 340 
targeted serum vancomycin concentrations (15-20 mg/mL) for nosocomial pneumonia caused by 341 
MRSA.12 Unfortunately, data on vancomycin trough concentrations from the local institution 342 
were not collected in this study.  The lower vancomycin dosage used could explain the lower 343 
clinical cure rates of the control group. Third, the treatment choice of nosocomial pneumonia 344 
caused by MSSA are beta-lactams because of their decreased incidence of relapse or increased 345 
resolution of signs and symptoms compared to vancomycin.  There were not many patients that 346 
had mono-microbial infections with Gram-positive pathogens, and the Gram-positive pathogens 347 
were not MRSA of which vancomycin has an indication for treating. 348 
The iclaprim dosages used in this study were weight based.  However, based on modeling 349 
of pharmacokinetics and pharmacodynamics, a fixed dosage of 80 mg of iclaprim showed a 30% 350 
increase in AUC/MIC and T/MIC, parameters associated with efficacy in animal models, while 351 
allowing for an approximately 10% decrease in Cmax, parameter associated with QTc 352 
prolongation.22  This fixed dosage of iclaprim is being studied in two Phase 3 studies for the 353 
treatment of acute bacterial skin and skin structure infections. 354 
Acknowledging the limitations of this Phase 2 study, the results suggest that iclaprim 355 
could be a useful and effective treatment option for nosocomial pneumonia due to Gram-positive 356 
pathogens especially because iclaprim is not nephrotoxic and does not required therapeutic drug 357 
monitoring nor renal dosing.  Three antibiotics are FDA approved for the treatment of 358 
nosocomial pneumonia caused by Gram-positive pathogens: vancomycin, linezolid and 359 
telavancin.  The recently published ATS/IDSA guidelines for the management of adults with 360 
HAP and VAP recommend use of either vancomycin or linezolid against susceptible MRSA, for 361 
the empiric treatment of suspected HAP or VAP in patients with risk factors for MRSA, those 362 
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being treated in units where >10%-20% of VAP/HAP S. aureus isolates are methicillin resistant, 363 
and when the prevalence of MRSA is not known.12  Despite the availability of vancomycin and 364 
linezolid, the 30-day all-cause mortality of patients with MRSA nosocomial pneumonia is 28%17 365 
to 60%.18 Resistance to vancomycin and linezolid is occasionally reported among patients treated 366 
for nosocomial pneumonia.19,20  For example, an outbreak with linezolid and methicillin-367 
resistance S. aureus in an intensive care department in Madrid, Spain, was reported.18  Among S. 368 
aureus isolates, the emergence of plasmid-transferable linezolid resistance mediated by the cfr 369 
gene was reported in some cases of VAP.18  Although relatively rare, the occurrence of cfr in 370 
MRSA isolates and its propensity to spread horizontally make it a significant concern for the 371 
treatment of hospital-acquired infections, including HAP, caused by S. aureus. Vancomycin is 372 
associated with nephrotoxicity, requires monitoring of trough concentrations, and adjusted 373 
dosaging in patients with renal impairment.  Linezolid is associated with myelosuppression, 374 
serotonin syndrome and hypoglycemia among patients receiving insulin or oral hypoglycemic 375 
agents.  Telavancin has black box safety warnings, the highest level of FDA safety warning, 376 
which include potential for QTc prolongation, potential birth defects when used by pregnant 377 
women, and GHFUHDVHGHIILFDF\LQSDWLHQWV\HDUVDQGLQWKRVHZLWKFUHDWLQLQHFOHDUDQFH50 378 
mL/minute. 379 
In the treatment of nosocomial pneumonia, it is critical that adequate concentrations of 380 
antibiotic(s) are achieved in the lower respiratory tract.  In a clinical study investigating the 381 
tissue distribution of a single IV dose of iclaprim in relevant lung compartments, high 382 
concentrations were found in epithelial ling fluid (ELF) and alveolar macrophages (AM), notably 383 
achieving levels up to 20- and 40-fold higher, respectively, than in plasma.10  In comparison, 384 
linezolid concentrates in ELF and AM at 3.3- and 0.14- fold, respectively; vancomycin 385 
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concentrates in ELF and AM at 0.25- and 2.5- fold, respectively.21  In addition, iclaprim 386 
concentrations in plasma, ELF and AM after a single IV dose of 1.6 mg/kg exceeded iclaprim 387 
MICs for penicillin- susceptible S. pneumoniae (MIC90 0.06 mg/L) and methicillin-resistant S. 388 
aureus (MIC90 0.12 mg/L) for up to 7 hours; mean iclaprim concentrations in ELF exceeded the 389 
iclaprim MICs observed for S. pneumoniae with intermediate penicillin resistance (MIC90
 
2 390 
mg/L) and full resistance (MIC90
 
4 mg/L) for up to 7 and 4 hours, respectively.  391 
In conclusion, in this shortened Phase 2 study, iclaprim was similar as vancomycin in the 392 
treatment of nosocomial pneumonia caused or suspected by Gram-positive organisms with 393 
respect to clinical cure rate and mortality rate at Day 28. These results warrant a pivotal clinical 394 
trial to evaluate the safety and efficacy of iclaprim for this indication. 395 
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